Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort

Haematologica. 2019 May;104(5):e208-e210. doi: 10.3324/haematol.2018.198820. Epub 2018 Dec 4.

Maria Winqvist^{1

2}, Per-Ola Andersson³, Anna Asklid², Karin Karlsson⁴, Claes Karlsson^{5

2}, Birgitta Lauri⁶, Jeanette Lundin^{5

2}, Mattias Mattsson⁷, Stefan Norin⁸, Anna Sandstedt⁹, Richard Rosenquist¹⁰, Florentin Späth¹¹, Lotta Hansson^{5

2}, Anders Österborg^{5

2}; Swedish CLL Group

¹ Department of Hematology, Karolinska University Hospital, Stockholm [email protected].
² Department of Oncology-Pathology, Karolinska Institutet, Stockholm.
³ Department of Hematology, Borås Hospital.
⁴ Department of Hematology, Lund University Hospital.
⁵ Department of Hematology, Karolinska University Hospital, Stockholm.
⁶ Department of Hematology, Sunderby Hospital, Sunderbyn-Luleå.
⁷ Department of Hematology, Uppsala University Hospital.
⁸ Department of Internal Medicine, Karolinska Institutet, Stockholm.
⁹ Department of Hematology, Linköping University Hospital.
¹⁰ Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm.
¹¹ Department of Radiation Sciences, Oncology, Umeå University, Sweden.

No abstract available

Publication types